Wrap Text
Swiss regulatory update
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.
10 April 2017
Swiss regulatory update
Mediclinic International plc, the international private healthcare group, today announces the
following updates in the regulatory environment of Hirslanden, its operating platform in
Switzerland.
In the Group’s interim results announcement on 10 November 2016, Mediclinic stated that
the canton of Zurich was considering a levy on the proportion of privately insured patients
treated in listed hospitals, including Klinik Hirslanden, known as the VVG levy and that the
Swiss national outpatient tariff (“TARMED”) was still in revision.
On Monday, 10 April 2017, the Zurich Cantonal Parliament voted not to approve the
proposed VVG levy.
On TARMED, the Swiss Federal Government has released proposed adjustments as a
transitional solution whilst healthcare providers and funders continue to negotiate and
agree a revised TARMED tariff structure. The government proposal is targeting annual
savings of around CHF700m across the public and private outpatient sectors. Outpatient
services contribute less than 20% of Hirslanden revenues. Due to its implementation date on
1 January 2018, the impact on Hirslanden is expected to be limited in the 2018 financial year
(to 31 March 2018). Based on initial analyses of the complex proposal, the expected
annualised impact on Hirslanden outpatient revenues could be around 10% before any
mitigating actions are considered which could include improved utilisation and increased
efficiencies.
The Zurich Cantonal Parliament has also approved an amendment to the cantonal hospital
law, providing a legal basis for the cantonal government to create a list of interventions that
in future should generally be treated as outpatient rather than inpatient services. The final
list of interventions will be agreed following a working group review.
Commenting today, Ole Wiesinger, CEO of Hirslanden, said:
“We acknowledge that the Zurich Cantonal Parliament has followed the recommendation of
the Finance Commission and voted not to approve the proposed Zurich VVG levy and
recognise that ongoing dialogue and engagement with the relevant public authorities is key
to ensuring that we can continue to deliver high-quality, cost-efficient, healthcare to our
patients.”
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern
Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core
purpose is to enhance the quality of life of patients by providing acute care, specialist-
orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in
Spire Healthcare Group plc (“Spire”), a LSE listed and UK-based private healthcare group.
Mediclinic International plc comprises 74 hospitals and 40 clinics. Mediclinic Southern Africa
operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia
with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care
facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic
Middle East operates 6 hospitals and 34 clinics with more than 700 inpatient beds in the
United Arab Emirates.
The platform contributions to Group revenue for the financial year end 2016 were
Hirslanden (53.6%), Southern Africa (30.8%) and the Middle East (15.6%).
During February 2016, the combination of the Company (previously named Al Noor Hospitals
Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic
International Limited was completed. Mediclinic International Limited was a South African
based international private healthcare group founded in 1983 and listed on the JSE, the
South African stock exchange, since 1986, with operations in South Africa, Namibia,
Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the
renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the
JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Ciara Martin
+44 (0)20 3727 1000
Frank Ford
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 10/04/2017 02:45:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
